New orphan drug (clobazam-Onfi) approved for Lennox-Gastaut seizures

young girl climbing wall  Some types of seizures are difficult to control. This is certainly true of Lennox-Gastaut syndrome. the FDA has approved cobazam (Onfi) as add-on therapy to treat seizures in children 2 years or older and adults. This is called an orphan drug since it is approved to treat a disease or condition that impacts 200,000 people or less.

Lennox-Gastaut is a particularly challenging kind of epilepsy for those suffering with the condition as well for clinicians trying to treat it. This syndrome usually starts at roughly 4 years of age and can also be caused by head injuries, central nervous system infections and metabolic conditions.

Additional information can be found at


Approval Date: 
Mon, 10/24/2011

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.